Back

Mineralocorticoid receptor antagonists as preventive therapy for atrial fibrillation

30 August 2026 (11:30 - 11:45)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation across the metabolic and life course spectrum Atrial Fibrillation (AF) ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor John J V McMurray

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
Metabolic disease and early rhythm control: insights from EAST AFNET 4
Professor P. Kirchhof (Hamburg, DE)
Slides Video
Presentation thumbnail
Dietary weight loss in persistent atrial fibrillation: what the LOSE AF Trial reveals, and what it does not
Doctor R. Wijesurendra (Oxford, GB)
Slides Video
Presentation thumbnail
Adverse pregnancy outcomes and long-term atrial fibrillation risk: insights from a national cohort
Professor K. Sundquist (Malmo, SE)
Slides Video

Access the full session

Session thumbnail
Atrial fibrillation across the metabolic and life course spectrum
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 11:30 CET
You may be interested in
thumbnail
Congress Presentation
Effects of mineralocorticoid receptor antagonists on new-onset or recurrent atrial fibrillation: a Bayesian and frequentist network meta-analysis of randomized trials.
31 August 2024
thumbnail
Congress Presentation
The impact of optimal heart failure therapy on prevention of atrial fibrillation
14 April 2026
thumbnail
Congress Presentation
nsMRAs: what emerging trials tell us about the future of heart failure therapy
18 May 2025
thumbnail
Congress Presentation
Discussant review - MRAs in heart failure
1 September 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources